• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (OP: NUMIF )

    0.0240 +0.0003 (+1.27%)
    Streaming Delayed Price Updated: 2:00 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,775
    Open 0.0220
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0237
    Today's Range 0.0220 - 0.0240
    52wk Range 0.0180 - 0.1550
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
    Via Benzinga
    Exposures Product Safety
    Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
    Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), announced on Thursday its third quarter financial results for the three months ended May 31, 2024."In... 
    Via Benzinga

    Performance

    YTD
    -72.88%
    -72.88%
    1 Month
    +7.14%
    +7.14%
    3 Month
    -25.70%
    -25.70%
    6 Month
    -70.48%
    -70.48%
    1 Year
    -80.00%
    -80.00%

    More News

    Read More
    Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
    Via Benzinga
    Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
    Via Benzinga
    Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
    Via Benzinga
    Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
    Via Benzinga
    Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
    Via Benzinga
    Why Is MindMed (MNMD) Stock Up 8% Today?
    Via InvestorPlace
    Exposures Product Safety
    Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
    Via Benzinga
    Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
    Via Benzinga
    30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
    Via Benzinga
    Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
    Via Benzinga
    Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
    Via Benzinga
    Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
    Via Benzinga
    NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
    Via Benzinga
    Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
    Via FinancialNewsMedia
    Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th
    From Virtual Investor Conferences
    Via GlobeNewswire
    MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
    Via Benzinga
    Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
    Via Benzinga
    Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
    Via Benzinga
    Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
    Via Benzinga
    Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
    Via Benzinga
    Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.